|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0019158,
umls-concept:C0019169,
umls-concept:C0021149,
umls-concept:C0024299,
umls-concept:C0199176,
umls-concept:C0209738,
umls-concept:C0392756,
umls-concept:C0439793,
umls-concept:C1514756,
umls-concept:C1742737
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2006-3-8
|
|
pubmed:abstractText |
Hepatitis B virus (HBV) infection is a common disease in China. Severe hepatitis is a well recognized complication in HBV carriers with malignant disease who receive cytotoxic chemotherapy. The objective of the current study was to assess the value of antiviral lamivudine for reducing the incidence and severity of hepatitis in HBV carriers with lymphoma who receive chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:GuanZhong-ZhenZZ,
pubmed-author:HeYi-FuYF,
pubmed-author:HeYou-JianYJ,
pubmed-author:HuangHui-QiangHQ,
pubmed-author:JiangWen-QiWQ,
pubmed-author:LiYu-HongYH,
pubmed-author:LinTong-YuTY,
pubmed-author:LinXu-BinXB,
pubmed-author:SunXiao-FeiXF,
pubmed-author:WangFen-HuaFH,
pubmed-author:XiaZhong-JunZJ,
pubmed-author:ZhangLiL
|
|
pubmed:copyrightInfo |
(c) 2006 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
106
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1320-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16470607-Administration, Oral,
pubmed-meshheading:16470607-Adolescent,
pubmed-meshheading:16470607-Adult,
pubmed-meshheading:16470607-Aged,
pubmed-meshheading:16470607-Anthracyclines,
pubmed-meshheading:16470607-Anti-HIV Agents,
pubmed-meshheading:16470607-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16470607-Child,
pubmed-meshheading:16470607-Dose-Response Relationship, Drug,
pubmed-meshheading:16470607-Female,
pubmed-meshheading:16470607-Hepatitis B,
pubmed-meshheading:16470607-Hepatitis B virus,
pubmed-meshheading:16470607-Hodgkin Disease,
pubmed-meshheading:16470607-Humans,
pubmed-meshheading:16470607-Incidence,
pubmed-meshheading:16470607-Lamivudine,
pubmed-meshheading:16470607-Lymphoma, Non-Hodgkin,
pubmed-meshheading:16470607-Male,
pubmed-meshheading:16470607-Middle Aged,
pubmed-meshheading:16470607-Neoplasm Recurrence, Local,
pubmed-meshheading:16470607-Neoplasm Staging,
pubmed-meshheading:16470607-Primary Prevention,
pubmed-meshheading:16470607-Prognosis,
pubmed-meshheading:16470607-Survival Rate,
pubmed-meshheading:16470607-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.
|
|
pubmed:affiliation |
Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in Southern China, 651 Dong Feng Road East, Guangzhou 510060, People's Republic of China.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Clinical Trial, Phase II
|
